Drugs may not delay onset of dementia; and moreNovember 27, 2007Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself. They have concluded that these drugs (cholinesterase inhibitors) do not seem to delay the appearance of Alzheimer disease or other forms of dementia. Three cholinesterase inhibitors - donepezil, rivastigmine and galantamine - are currently approved for use in mild-to-moderate Alzheimer disease. Some experts are not convinced that they are effective, but other experts and patient support groups have called for the drugs to be given to people with "mild cognitive impairment (MCI)" - the term that is used to describe the condition where people have memory problems that are more severe than those normally seen in others of their age, but otherwise have no symptoms of dementia. It is believed that people with MCI are at high risk of developing Alzheimer disease. Dr Raschetti and colleagues at Italy's National Centre for Epidemiology, Surveillance and Health Promotion in Rome conducted a systematic review of the data from clinical trials that had addressed the use of cholinesterase inhibitors with MCI patients. In none of the six trials that they examined did the use of the drugs significantly reduce the rate of progression from MCI to dementia.
One problem that came to light during their review was that there is no generally accepted precise definition for MCI. There was therefore some variation between the trials in the mental state of the people given the drugs. Dr Raschetti and his team have called for more clinical trials to be done, but using a single agreed definition of mild cognitive impairment. Until such trials have found a benefit from using cholinesterase inhibitors in this way, there seems to be no justification for doctors to do so in clinical practice. Public Library of Science | |||||||||||||||||||||
|
Related Dementia Current Events and Dementia News Articles Has a new era of reinstitutionalization in mental health care begun? A retrospective analysis of hospital episode statistics, involuntary admissions under the Mental Health Act 1983, and the number of psychiatric beds in England 1996-2006. New study proves that pain is not a symptom of arthritis, pain causes arthritis Pain is more than a symptom of osteoarthritis, it is an inherent and damaging part of the disease itself, according to a study published today in journal Arthritis and Rheumatism. Study confirms benefit of combination therapy for Alzheimer's disease Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Inflammatory response to infection and injury may worsen dementia Inflammation in the brain resulting from infection or injury may accelerate the progress of dementia, research funded by the Wellcome Trust suggests. Researchers seeking to identify Alzheimer's risk focus on specific blood biomarker A simple blood test to detect whether a person might develop Alzheimer's disease is within sight and could eventually help scientists in their quest toward reversing the disease's onset in those likely to develop the debilitating neurological condition. Changes in urine could lead to BSE test for live animals Researchers have demonstrated that protein levels in urine samples can indicate both the presence and progress of Bovine Spongiform Encephalopathy (BSE) disease in cattle. Obese people with asthma have nearly 5 times greater risk of hospitalization for asthma Obese people who have asthma are nearly five times more likely to be hospitalized for the condition than non-obese people with asthma, according to a Kaiser Permanente study published in the September issue of the Journal of Allergy and Clinical Immunology. Anti-psychotic drug use in the elderly increases despite drug safety warnings Three regulatory warnings of serious adverse events slowed the growth of use of atypical antipsychotic drugs among elderly patients with dementia, but they did not reduce the overall prescription rate of these drugs. MIT zeroes in on Alzheimer's structures MIT engineers report a new approach to identifying protein structures key to Alzheimer's disease, an important step toward the development of new drugs that could prevent such structures from forming. Study examines testing model to predict and diagnose new cases of dementia A report published by researchers at Albert Einstein College of Medicine of Yeshiva University in the August 20 issue of JAMA suggests that measuring how much an individual's performance varies across several neuropsychological tests enhances the accuracy of predicting whether older adults will develop dementia. More Dementia Current Events and Dementia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||